Sciences behind
Highly effective in inhibiting polymicrobial growth
Against other pathogenic bacteria and fungus
Besides, Lassica K014™ is found to be equally effective in inhibiting other fungal-bacterial colonisation, including Escherichia coli, Propionibacterium acnes and Candida albicans. This broad-spectrum activity reduces the risks of enhanced pathogenicity of co-infections attributable to polymicrobial interaction of Staphylococcus aureus and Candida albicans in human guts.
Against MRSA
Our studies found that Lassica K014™ is capable of killing 96.1% of Methicillin-resistant Staphylococcus aureus (MRSA) colonies, which is comparable to commercially available antibiotics such as ampicillin, chloramphenicol and vancomycin.
Commensal bacteria and fungi cell counts in the faeces of healthy laboratory rats before and after oral administration of Lassica K014™ within 24 hours
Under the scanning electron microscopy, it is observed that MRSA cell structures rupture when treated with Lassica K014™ (see figure below).
Control
Treated with
Lassica K014™
Comparing Anti-MRSA Activities of Lassica K014™ with Antibiotics
Promoting balanced microbiota in gut
Our in-house animal study shows that single dose of Lassica K014™ increases lactic acid bacteria (LAB) cell counts within 24 hours (see diagram below) and reduces the opportunistic pathogens. Studies found that polymicrobial interaction of these opportunistic pathogens in human guts can contribute to enhanced pathogenicity of co-infections. This suggests that the use of Lassica K014™ can have positive impact on gut health.
Inhibitory efficacy % against other pathogens
Escherichia coli
Candida albicans
Propionibacterium acnes
Streptococcus mutans